Phase II results for investigational Covid-19 antibody otilimab in hospitalised Covid-19 patients
Overall, a single dose of otilimab did not result in a statistically significant increase in the number of COVID-19 patients who remained alive and free of respiratory failure at 28 days. However pre-planned analysis by age suggested benefit in patients ≥70 years (65.1% v 45.9%)
Source:
PharmaTimes